Actinium’s radiotherapy push gains IP depth as ATNM-400 heads to SNMMI 2026
Actinium’s science story is widening, but its balance sheet pressure is now impossible to ignore. ATNM-400 data may decide the next chapter.
Pharma & Biotech
Pharma & Biotech
Can Actinium’s ATNM-400 radiotherapy reshape treatment for resistant breast cancer?
Actinium Pharmaceuticals, Inc. has presented new preclinical data for its alpha-particle radiotherapy candidate ATNM-400 at the 2025 San Antonio Breast Cancer Symposium (SABCS), highlighting potent anti-tumor activity across hormone receptor–positive, triple-negative, and therapy-resistant breast cancer models. The findings suggest that ATNM-400 could become a differentiated treatment option for patients with tumors that have progressed after